Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
2024年4月30日 - 5:16AM
ビジネスワイヤ（英語）
-- 10 academic scholarships awarded supporting
siblings of Rett syndrome patients
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it has awarded 10 academic scholarships to eligible recipients of
the first Rett Sibling Scholarship. The Rett Sibling Scholarship
program, sponsored by Acadia, was established in 2023 to recognize
the siblings of individuals with Rett syndrome. This year’s
recipients will each receive $5,000 to pursue their goals in higher
education for the 2024-25 academic school year.
“Families affected by Rett syndrome navigate many challenges,
from medical care to balancing family, work and the daily
activities of life and financial strain. Siblings often contribute
by helping parents with caregiving and being a loving, supportive
sibling, while also pursuing their own goals,” said Bill Keller,
Acadia’s Vice President, Patient Advocacy and Industry Relations.
“In establishing the Rett Scholarship program Acadia seeks to
recognize their resilience and contributions while providing
support in pursuit of their academic goals. This is another example
of our ongoing commitment to understanding and supporting the needs
of the Rett syndrome community.”
This year’s array of recipients includes students from Arizona,
Arkansas, California, Colorado, New Jersey, New York, Oregon,
Wisconsin, and Utah who are planning to pursue studies ranging from
psychology to finance and medicine.
“The Rett Sibling Scholarship recognizes my personal
aspirations, which are inspired by my relationship with my sister,
and reminds me that siblings like me are not alone in our
journeys,” said Kate Koblegarde, one of this year’s Rett Sibling
Scholarship recipients. “I’m interested in social justice because
I’ve seen all that my sister can do with support, as well as the
barriers she faces. I know there is more work to be done to ensure
everyone can pursue their own dreams.”
The Rett Sibling Scholarship
The Rett Sibling Scholarship, sponsored by Acadia
Pharmaceuticals Inc., aims to shine a light on these often-unsung
heroes of the Rett community. Submission and review of the
applications is independently administered by International
Scholarship and Tuition Services, Inc. (ISTS), a firm that
specializes in managing sponsored scholarship programs.
To learn more about the Rett Sibling Scholarship and this year’s
recipients, visit RettScholarship.com. Details regarding the
2025-2026 academic school year application period will be shared in
the fourth quarter of 2024.
About Rett Syndrome
Rett syndrome is a rare, complex, neurodevelopmental disorder
that may occur over four stages and affects approximately 6,000 to
9,000 patients in the U.S., with approximately 5,000 patients
currently diagnosed according to an analysis of healthcare claims
data.1-4 A child with Rett syndrome exhibits an early period of
apparently normal development until six to 18 months, when their
skills seem to slow down or stagnate. This is typically followed by
a duration of regression when the child loses acquired
communication skills and purposeful hand use. The child may then
experience a plateau period in which they show mild recovery in
cognitive interests, but body movements remain severely diminished.
As they age, those living with Rett may continue to experience a
stage of motor deterioration which can last the rest of the
patient’s life.3 Rett syndrome is typically caused by a genetic
mutation on the MECP2 gene.5 In preclinical studies, deficiency in
MeCP2 function has been shown to lead to impairment in synaptic
communication, and the deficits in synaptic function may be
associated with Rett manifestations.5-7
Symptoms of Rett syndrome may also include development of hand
stereotypies, such as hand wringing and clapping, and gait
abnormalities.8 Most Rett patients typically live into adulthood
and require round-the-clock care.2,9
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on treating Prader-Willi syndrome,
Alzheimer’s disease psychosis and multiple other programs targeting
neuropsychiatric symptoms in central nervous system disorders. For
more information, visit us at Acadia.com and follow us on LinkedIn
and Twitter.
References
1 Acadia Pharmaceuticals Inc., Data on file. RTT US Prevalence.
March 2022. 2 Fu C, Armstrong D, Marsh E, et al. Consensus
guidelines on managing Rett syndrome across the lifespan. BMJ
Paediatrics Open. 2020; 4: 1-14. 3 Kyle SM, Vashi N, Justice MJ.
Rett syndrome: a neurological disorder with metabolic components.
Open Biol. 2018; 8: 170216. 4 Acadia Pharmaceuticals Inc., Data on
file. 5 Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is
caused by mutations in X-linked MECP2, encoding methyl-CpG-binding
protein 2. Nat Genet. 1999; 23(2): 185-188. 6 Fukuda T, Itoh M,
Ichikawa T, et al. Delayed maturation of neuronal architecture and
synaptogenesis in cerebral cortex of Mecp2-deficient mice. J
Neuropathol Exp Neurol. 2005; 64(6): 537-544. 7 Asaka Y, Jugloff
DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in
the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006;
21(1): 217-227. 8 Neul JL, Kaufmann WE, Glaze DG, et al. Rett
syndrome: revised diagnostic criteria and nomenclature. Ann Neurol.
2010; 68(6): 944-950. 9 Daniel C, Tarquinio DO, Hou W, et al. The
changing face of survival in Rett syndrome and MECP2-related
disorders. Pediatr Neurol. 2015; 53(5): 402-411.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429582852/en/
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
過去 株価チャート
から 2 2025 まで 3 2025
Acadia Pharmaceuticals (NASDAQ:ACAD)
過去 株価チャート
から 3 2024 まで 3 2025
